TN2017000204A1 - Triazolopyrimidine compounds and uses thereof - Google Patents

Triazolopyrimidine compounds and uses thereof

Info

Publication number
TN2017000204A1
TN2017000204A1 TN2017000204A TN2017000204A TN2017000204A1 TN 2017000204 A1 TN2017000204 A1 TN 2017000204A1 TN 2017000204 A TN2017000204 A TN 2017000204A TN 2017000204 A TN2017000204 A TN 2017000204A TN 2017000204 A1 TN2017000204 A1 TN 2017000204A1
Authority
TN
Tunisia
Prior art keywords
sup
triazolopyrimidine compounds
triazolopyrimidine
compounds
prc2
Prior art date
Application number
TN2017000204A
Other languages
English (en)
Inventor
Ho Man Chan
Xiang-Ju Justin Gu
Ying Huang
Ling Li
Yuan Mi
Wei Qi
Martin Sendzik
Yongfeng Sun
Long Wang
Zhengtian Yu
Hailong Zhang
Ji Yue Zhang (Jeff)
Man Zhang
Qiong Zhang
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2017000204A1 publication Critical patent/TN2017000204A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2017000204A 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof TN2017000204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
TN2017000204A1 true TN2017000204A1 (en) 2018-10-19

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2017000204A TN2017000204A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Country Status (40)

Country Link
US (5) US10220036B2 (OSRAM)
EP (1) EP3237418B1 (OSRAM)
JP (1) JP6736559B2 (OSRAM)
KR (1) KR102534028B1 (OSRAM)
CN (1) CN107108637B (OSRAM)
AU (1) AU2015370524B2 (OSRAM)
BR (1) BR112017010354B8 (OSRAM)
CA (1) CA2969090C (OSRAM)
CL (1) CL2017001572A1 (OSRAM)
CO (1) CO2017005992A2 (OSRAM)
CR (1) CR20170285A (OSRAM)
CY (1) CY1121901T1 (OSRAM)
DK (1) DK3237418T3 (OSRAM)
DO (1) DOP2017000149A (OSRAM)
EA (1) EA032416B1 (OSRAM)
EC (1) ECSP17047153A (OSRAM)
ES (1) ES2722048T3 (OSRAM)
GT (1) GT201700146A (OSRAM)
HR (1) HRP20190805T1 (OSRAM)
HU (1) HUE043060T2 (OSRAM)
IL (1) IL252135B (OSRAM)
JO (1) JO3489B1 (OSRAM)
LT (1) LT3237418T (OSRAM)
ME (1) ME03385B (OSRAM)
MX (1) MX375970B (OSRAM)
MY (1) MY186837A (OSRAM)
NZ (1) NZ731664A (OSRAM)
PE (1) PE20171307A1 (OSRAM)
PH (1) PH12017501016B1 (OSRAM)
PL (1) PL3237418T3 (OSRAM)
PT (1) PT3237418T (OSRAM)
RS (1) RS58679B1 (OSRAM)
SG (1) SG11201703880VA (OSRAM)
SI (1) SI3237418T1 (OSRAM)
SV (1) SV2017005472A (OSRAM)
TN (1) TN2017000204A1 (OSRAM)
TW (1) TWI694076B (OSRAM)
UA (1) UA120945C2 (OSRAM)
UY (1) UY36462A (OSRAM)
WO (1) WO2016103155A1 (OSRAM)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190805T1 (hr) * 2014-12-23 2019-06-28 Novartis Ag Spojevi triazolopirimidina i njihova uporaba
JP7121660B2 (ja) * 2016-06-01 2022-08-18 エピザイム，インコーポレイティド 癌を処置するためのｅｚｈ２阻害剤の使用
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
KR102519922B1 (ko) * 2016-06-20 2023-04-11 노파르티스 아게 트리아졸로피리미딘 화합물의 결정질 형태
CN109790166A (zh) * 2016-06-20 2019-05-21 诺华股份有限公司 咪唑并吡啶化合物用于治疗癌症
PE20190624A1 (es) 2016-07-12 2019-04-26 Revolution Medicines Inc 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
CN117327075A (zh) 2017-01-23 2024-01-02 锐新医药公司 作为变构shp2抑制剂的二环化合物
EP3571189B1 (en) 2017-01-23 2023-03-29 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3054976A1 (en) * 2017-03-16 2018-09-20 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
AU2018347516A1 (en) 2017-10-12 2020-05-07 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
EP3724189B1 (en) * 2017-12-15 2023-10-04 Revolution Medicines, Inc. Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
CN111630042A (zh) * 2018-01-23 2020-09-04 巴斯夫欧洲公司 吡啶衍生物的卤化
WO2019152419A1 (en) * 2018-01-31 2019-08-08 Mirati Therapeutics, Inc Prc2 inhibitors
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
TW202039498A (zh) * 2018-11-30 2020-11-01 大陸商上海拓界生物醫藥科技有限公司 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
PH12021552217A1 (en) * 2019-03-15 2022-06-13 Fulcrum Therapeutics Inc Macrocyclic azolopyridine derivatives as eed and prc2 modulators
WO2020204024A1 (ja) * 2019-04-03 2020-10-08 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
WO2020247475A1 (en) * 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
WO2021011713A1 (en) 2019-07-16 2021-01-21 The Regents Of The University Of Michigan Imidazopyrimidines as eed inhibitors and the use thereof
PH12022550441A1 (en) * 2019-08-22 2022-12-19 Blueray Therapeutics Shanghai Co Ltd Azaheteroaryl compound and application thereof
KR102889562B1 (ko) 2019-09-26 2025-11-24 노파르티스 아게 아자-퀴놀린 화합물 및 그의 용도
US20230028221A1 (en) * 2019-11-01 2023-01-26 Shanghaitech University Eed inhibitor, and preparation method therefor and use thereof
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
US12221427B2 (en) * 2020-05-11 2025-02-11 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2,3-dihydrobenzofuran-4-yl)methanamine or its salt, and intermediates thereof
EP4157279A1 (en) * 2020-05-28 2023-04-05 Novartis AG Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) * 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN115703799B (zh) * 2021-08-11 2024-11-08 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
WO2003034997A2 (en) * 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
NZ535101A (en) 2002-03-08 2007-07-27 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
MXPA04008893A (es) 2002-03-13 2005-06-20 Array Biopharma Inc Derivados de bencimidazol n3 alquilados como inhibidores de mek.
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
CA2673784A1 (en) 2006-12-27 2008-07-10 Usc Stevens-University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
JP5658565B2 (ja) 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
PH12012502194A1 (en) * 2010-05-07 2014-09-05 Glaxosmithkline Llc Indoles
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
TR201904660T4 (tr) 2012-03-12 2019-05-21 Epizyme Inc İnsan EZH2 inhibitörleri ve bunun kullanım yöntemleri.
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
JP2016509014A (ja) 2013-02-08 2016-03-24 ステムセントリックス， インコーポレイテッド 新規の多特異的構成物
KR102219441B1 (ko) 2013-02-11 2021-02-23 콘스텔레이션 파마슈티칼스, 인크. 메틸 변형 효소 조절제, 이의 조성물 및 용도
HK1220916A1 (zh) 2013-03-14 2017-05-19 基因泰克公司 治疗癌症和预防癌症药物抗性的方法
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3104706B1 (en) 2014-02-11 2022-03-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
BR112017009784B1 (pt) 2014-11-14 2021-12-28 Basf Se Usos de um composto, misturas agroquímicas, método para reduzir a nitrificação e método para tratar um fertilizante
ES2668688T3 (es) 2014-12-16 2018-05-21 Omya International Ag Carbonato de calcio para protección vegetal
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20190805T1 (hr) * 2014-12-23 2019-06-28 Novartis Ag Spojevi triazolopirimidina i njihova uporaba

Also Published As

Publication number Publication date
DK3237418T3 (da) 2019-05-13
IL252135B (en) 2020-06-30
PH12017501016A1 (en) 2017-12-11
PT3237418T (pt) 2019-05-23
DOP2017000149A (es) 2017-07-15
US20160176882A1 (en) 2016-06-23
BR112017010354B1 (pt) 2022-09-20
US11207325B2 (en) 2021-12-28
EP3237418B1 (en) 2019-01-30
GT201700146A (es) 2019-06-12
CR20170285A (es) 2017-08-21
AU2015370524B2 (en) 2018-11-01
SI3237418T1 (sl) 2019-06-28
ES2722048T3 (es) 2019-08-07
BR112017010354A2 (pt) 2017-12-26
IL252135A0 (en) 2017-07-31
JP6736559B2 (ja) 2020-08-05
US9580437B2 (en) 2017-02-28
PH12017501016B1 (en) 2017-12-11
TW201629065A (zh) 2016-08-16
HUE043060T2 (hu) 2019-07-29
WO2016103155A1 (en) 2016-06-30
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
UY36462A (es) 2016-07-29
EA032416B1 (ru) 2019-05-31
SG11201703880VA (en) 2017-07-28
BR112017010354B8 (pt) 2022-10-18
CY1121901T1 (el) 2020-10-14
MY186837A (en) 2021-08-25
NZ731664A (en) 2024-02-23
US20230033320A1 (en) 2023-02-02
UA120945C2 (uk) 2020-03-10
AU2015370524A1 (en) 2017-06-01
MX2017008529A (es) 2017-10-25
ECSP17047153A (es) 2019-02-28
CN107108637A (zh) 2017-08-29
RS58679B1 (sr) 2019-06-28
PL3237418T3 (pl) 2019-07-31
US20200323859A1 (en) 2020-10-15
US20170348312A1 (en) 2017-12-07
CO2017005992A2 (es) 2017-10-20
JO3489B1 (ar) 2020-07-05
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
CA2969090C (en) 2023-05-02
MX375970B (es) 2025-03-06
CA2969090A1 (en) 2016-06-30
CL2017001572A1 (es) 2018-01-12
US11931363B2 (en) 2024-03-19
CN107108637B (zh) 2019-10-29
EP3237418A1 (en) 2017-11-01
LT3237418T (lt) 2019-05-10
KR20170095882A (ko) 2017-08-23
HRP20190805T1 (hr) 2019-06-28
ME03385B (me) 2020-01-20
SV2017005472A (es) 2018-06-12
EA201791420A1 (ru) 2017-10-31
JP2018500342A (ja) 2018-01-11
KR102534028B1 (ko) 2023-05-19

Similar Documents

Publication Publication Date Title
TN2017000204A1 (en) Triazolopyrimidine compounds and uses thereof
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
MX2021014128A (es) Polimorfos de selinexor.
NZ715776A (en) Polymorph of syk inhibitors
PH12016500225B1 (en) Novel quinoline-substituted compound
MY197698A (en) Oxysterols and methods of use thereof
PH12017500095A1 (en) Imidazopyridazine compounds
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
MX357763B (es) Tratamiento para cancer pancreatico.
ZA201606471B (en) Antimitotic amides for the treatment of cancer and proliferative disorders
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
PH12015502703A1 (en) Pharmaceutical compositions
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ767083A (en) Polymorphs of selinexor
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents